Home › Pancreatic Cancer › NCT06151223
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Age ≥ 18 year * Able to provide written informed consent * Meets criteria as a High-Risk Individual as defined by protocol Exclusion Criteria: * Individual who has a personal history of pancreatic ductal adenocarcinoma (PDAC) * History of total pancreatectomy
About the study
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.
What is being tested
- Bio-specimen Collection: Blood (other)
- Bio-specimen Collection: Pancreatic Juice (other)
- MRI (diagnostic test)
Sponsor: Mayo Clinic · Participants: 5,000 · Started: Jul 13, 2021
Contact the study team
- Clinical Trials Referral Office · Phone: 855-776-0015
Official record on ClinicalTrials.gov — NCT06151223
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.